316 related articles for article (PubMed ID: 19433112)
21. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.
DeBuysscher BL; Scott D; Marzi A; Prescott J; Feldmann H
Vaccine; 2014 May; 32(22):2637-44. PubMed ID: 24631094
[TBL] [Abstract][Full Text] [Related]
22. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.
Zhu Z; Dimitrov AS; Bossart KN; Crameri G; Bishop KA; Choudhry V; Mungall BA; Feng YR; Choudhary A; Zhang MY; Feng Y; Wang LF; Xiao X; Eaton BT; Broder CC; Dimitrov DS
J Virol; 2006 Jan; 80(2):891-9. PubMed ID: 16378991
[TBL] [Abstract][Full Text] [Related]
23. Hendra virus and Nipah virus animal vaccines.
Broder CC; Weir DL; Reid PA
Vaccine; 2016 Jun; 34(30):3525-34. PubMed ID: 27154393
[TBL] [Abstract][Full Text] [Related]
24. Prefusion stabilization of the Hendra and Langya virus F proteins.
Byrne PO; Blade EG; Fisher BE; Ambrozak DR; Ramamohan AR; Graham BS; Loomis RJ; McLellan JS
J Virol; 2024 Feb; 98(2):e0137223. PubMed ID: 38214525
[TBL] [Abstract][Full Text] [Related]
25. Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.
Defang GN; Khetawat D; Broder CC; Quinnan GV
Vaccine; 2010 Dec; 29(2):212-20. PubMed ID: 21050901
[TBL] [Abstract][Full Text] [Related]
26. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins.
Dang HV; Cross RW; Borisevich V; Bornholdt ZA; West BR; Chan YP; Mire CE; Da Silva SC; Dimitrov AS; Yan L; Amaya M; Navaratnarajah CK; Zeitlin L; Geisbert TW; Broder CC; Veesler D
Nat Struct Mol Biol; 2021 May; 28(5):426-434. PubMed ID: 33927387
[TBL] [Abstract][Full Text] [Related]
27. Evidence for henipavirus spillover into human populations in Africa.
Pernet O; Schneider BS; Beaty SM; LeBreton M; Yun TE; Park A; Zachariah TT; Bowden TA; Hitchens P; Ramirez CM; Daszak P; Mazet J; Freiberg AN; Wolfe ND; Lee B
Nat Commun; 2014 Nov; 5():5342. PubMed ID: 25405640
[TBL] [Abstract][Full Text] [Related]
28. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
Foster SL; Woolsey C; Borisevich V; Agans KN; Prasad AN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Cross RW; Geisbert TW
Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2200065119. PubMed ID: 35286211
[TBL] [Abstract][Full Text] [Related]
29. High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test.
Konduru K; Shurtleff AC; Bavari S; Kaplan G
J Virol Methods; 2018 Apr; 254():1-7. PubMed ID: 29355585
[TBL] [Abstract][Full Text] [Related]
30. Development of a neutralization assay using a vesicular stomatitis virus expressing Nipah virus glycoprotein and a fluorescent protein.
Jain S; Lo MK; Kainulainen MH; Welch SR; Spengler JR; Satter SM; Rahman MZ; Hossain ME; Chiang CF; Klena JD; Bergeron É; Montgomery JM; Spiropoulou CF; Albariño CG
Virology; 2023 Oct; 587():109858. PubMed ID: 37544045
[TBL] [Abstract][Full Text] [Related]
31. Establishment of an immunofluorescence assay to detect IgM antibodies to Nipah virus using HeLa cells expressing recombinant nucleoprotein.
Kaku Y; Park ES; Noguchi A; Inoue S; Lunt R; Malbas FF; Demetria C; Neoh HM; Jamal R; Morikawa S
J Virol Methods; 2019 Jul; 269():83-87. PubMed ID: 30954461
[TBL] [Abstract][Full Text] [Related]
32. Antigen capture ELISA system for henipaviruses using polyclonal antibodies obtained by DNA immunization.
Kaku Y; Noguchi A; Marsh GA; Barr JA; Okutani A; Hotta K; Bazartseren B; Broder CC; Yamada A; Inoue S; Wang LF
Arch Virol; 2012 Aug; 157(8):1605-9. PubMed ID: 22585045
[TBL] [Abstract][Full Text] [Related]
33. Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.
Chattopadhyay A; Rose JK
J Virol; 2011 Mar; 85(5):2004-11. PubMed ID: 21177820
[TBL] [Abstract][Full Text] [Related]
34. Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model.
Guillaume V; Wong KT; Looi RY; Georges-Courbot MC; Barrot L; Buckland R; Wild TF; Horvat B
Virology; 2009 May; 387(2):459-65. PubMed ID: 19328514
[TBL] [Abstract][Full Text] [Related]
35. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine.
Mungall BA; Middleton D; Crameri G; Bingham J; Halpin K; Russell G; Green D; McEachern J; Pritchard LI; Eaton BT; Wang LF; Bossart KN; Broder CC
J Virol; 2006 Dec; 80(24):12293-302. PubMed ID: 17005664
[TBL] [Abstract][Full Text] [Related]
36. Transcriptome Profiling of the Virus-Induced Innate Immune Response in Pteropus vampyrus and Its Attenuation by Nipah Virus Interferon Antagonist Functions.
Glennon NB; Jabado O; Lo MK; Shaw ML
J Virol; 2015 Aug; 89(15):7550-66. PubMed ID: 25972557
[TBL] [Abstract][Full Text] [Related]
37. Nipah and Hendra Virus Glycoproteins Induce Comparable Homologous but Distinct Heterologous Fusion Phenotypes.
Bradel-Tretheway BG; Zamora JLR; Stone JA; Liu Q; Li J; Aguilar HC
J Virol; 2019 Jul; 93(13):. PubMed ID: 30971473
[TBL] [Abstract][Full Text] [Related]
38. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.
Bossart KN; Crameri G; Dimitrov AS; Mungall BA; Feng YR; Patch JR; Choudhary A; Wang LF; Eaton BT; Broder CC
J Virol; 2005 Jun; 79(11):6690-702. PubMed ID: 15890907
[TBL] [Abstract][Full Text] [Related]
39. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.
Lo MK; Bird BH; Chattopadhyay A; Drew CP; Martin BE; Coleman JD; Rose JK; Nichol ST; Spiropoulou CF
Antiviral Res; 2014 Jan; 101():26-9. PubMed ID: 24184127
[TBL] [Abstract][Full Text] [Related]
40. Animal models of henipavirus infection: a review.
Weingartl HM; Berhane Y; Czub M
Vet J; 2009 Sep; 181(3):211-20. PubMed ID: 19084436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
